The $3 billion launch of a biotech focused on cellular rejuvenation was 2022’s largest healthcare venture capital deal in the U.S. and Europe.
That’s according to a ranking provided to Medical Design & Outsourcing by Silicon Valley Bank (SVB), which ranked the deals using its own proprietary information and data from Pitchbook.
The biopharma sector represented three of the 10 largest VC deals. Diagnostics/tools had two deals on the list, taking the No. 2 and 3 spots. The healthtech sector had four deals on the list.
Only one device developer ranked in 2022’s top 10, just like the year before, when CMR Surgical’s $600 million Series D financing round was the fifth-largest deal of 2021. (Healthtech deals dominated the prior-year list by taking six of the 10 spots, including the top four. There were three biopharma deals in the prior-year ranking, but none from the diagnostics/tools sector.)
Learn more about 2022’s biggest healthcare VC deals in the U.S. and Europe in the pages that follow: